Company profile
Assembly Biosciences, Inc.
NASDAQ: ASMB · Healthcare · Biotechnology
#387 of 1,422 Healthcare companies by revenuetop-quartile growth
EA Score
63CFH 71DQ 54GM 56SS 66
v0.1 · 65/100 weight · provisional
↑ revenue growth (YoY), balance-sheet leverage · ↓ growth stability, disclosure history
Methodology →Revenue TTM
$74.8M
Rev growth YoY (TTM)
+125.1%
Net income (FY)
-$6.1M
Employees
73
as of 2026-08-12
Market cap
$540.4M
as of 2026-08-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$72.3M$72.3M2025
Net income-$6.1M-$6.1M2025
Operating income-$12.1M-$12.1M2025
Total assets$257.6M$257.6M2025
Liabilities$50.8M$50.8M2025
Equity$206.8M$206.8M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY23
FY23
FY25
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Assembly Biosciences, Inc.’s revenue?
Assembly Biosciences, Inc. booked $72.3M in FY2025 revenue, growing 154% year over year — faster than most Healthcare companies we track, at a -8.5% net margin.
Peers · Healthcare
Recursion Pharmaceuticals, Inc.54DHealwell AI Inc.60COmeros Corporation65BCue Health Inc.——Avita Medical Inc.50DViridian Therapeutics, Inc.66BNeighbors
San Mateo →Key facts
CEOJason A. Okazaki
SectorHealthcare
IndustryBiotechnology
HeadquartersSouth San Francisco, CA
ExchangeNASDAQ: ASMB
Employees73
IPO date2010-12-17
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.